logo
Plus   Neg
Share
Email

Skyhawk, Vertex Enter Into Research Collaboration On Serious Diseases

Skyhawk Therapeutics Inc. and Vertex Pharmaceuticals Inc. (VRTX) has formed a strategic collaboration to discover and develop novel small molecules that modulate RNA splicing for the treatment of serious diseases.

As per the collaboration deal, Vertex will pay Skyhawk $40 million upfront. Skyhawk will grant Vertex options to exclusively license worldwide intellectual property rights to candidates discovered and developed under the collaboration that are directed to program targets.

Vertex will be responsible for further development and commercialization.
Skyhawk is also eligible to receive up to $2.2 billion in potential milestone payments, as well as potential royalties on future sales.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chipotle Mexican Grill, Inc. is teaming with e.l.f. Cosmetics to launch a limited edition beauty collection on March 10, aiming to support plant-based lifestyles and responsibly-sourced products. The e.l.f. x Chipotle makeup collection will comprise cruelty-free and vegan products inspired by Chipotle's responsibly-raised food. The United Kingdom's Competition and Markets Authority (CMA) has launched an investigation into technology giant Apple Inc. (AAPL) following complaints that its terms and conditions for app developers are unfair and anti-competitive. iPhone maker Apple also operates the App Store, which is the only... Supermarket chain Kroger Co. on Thursday reported that it posted a loss for the fourth quarter compared to a profit last year, hurt by pension plan withdrawal liabilities. Adjusted earnings per share topped analysts' estimates, while quarterly revenues missed it. However, the company initiated adjusted earning guidance for the full-year 2021, well above analysts' estimates.
Follow RTT